Skip to content

Impact of pharmacist interventions on adherence and patient outcomes among depressed patients.

Impact of pharmacist interventions on adherence and measurable patient outcomes among depressed patients: a randomised controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN34879893
Enrollment
195
Registered
2014-12-30
Start date
2014-02-10
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with major depression disorders Mental and Behavioural Disorders Depression

Interventions

The intervention focused on the enhancement of the patients’ involvement in decision ?making, their beliefs towards antidepressants and their knowledge about ?antidepressants?. Pharmacists followed t

Sponsors

Al Amal Psychiatric Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients within the age range of 18 to 60 years 2. Patients newly diagnosed with a MDD, according to the scales in the ?Diagnostic and Statistical Manual of Mental Disorders, 4th Ed (DSM-IV) 3. Patients having no psychotic or bipolar history 4. Patients having no drug or dependency history 5. Patients having no cognitive impairment that may hinder the assessment?

Exclusion criteria

Exclusion criteria: 1. Patients having a psychiatric or bipolar disorder history 2. Patients having drug or dependency history. 3. Patients suffering from any cognitive impairment that may hinder the ?assessment 4. Patients not responding at any level to the antidepressant within 8 weeks of ?recruitment

Design outcomes

Primary

MeasureTime frame
Adherence measured by ?Medication Adherence Scale (MMAS) at baseline, 3 months and 6 months

Secondary

MeasureTime frame
1. Patients’ beliefs about medicine measured by Beliefs About Medicine Questionnaire (BMQ) 2. Severity of depression ? measured by MADRS scale 3. Patients’ involvement in decisions 4. Health-related quality of life - measured by EuroQOL-5D 5. Patient satisfaction with treatment Measured at baseline, 3 months and 6 months.

Countries

Saudi Arabia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026